Cargando…

Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study

Algeria has adopted a therapeutic protocol using hydroxychloroquine (HCQ) as a first-line treatment for patients with coronavirus disease 2019 (COVID-19). The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zohra, Saadi Fatima, Nassima, Lachgueur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635677/ https://www.ncbi.nlm.nih.gov/pubmed/34868713 http://dx.doi.org/10.1080/20961790.2021.1936896

Ejemplares similares

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine
por: Sahraei, Zahra, et al.
Publicado: (2020)

A Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine
por: Mukherjee, Aveek, et al.
Publicado: (2020)

Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?
por: Ippolito, Matthew M, et al.
Publicado: (2020)

Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy
por: Macías, Juan, et al.
Publicado: (2021)

Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study
por: Garcia, Philippe, et al.
Publicado: (2020)

Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment
por: Carbillon, Lionel, et al.
Publicado: (2021)

Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal
por: Khuroo, Mohammad Sultan
Publicado: (2020)

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
por: Satlin, Michael J., et al.
Publicado: (2020)

QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
por: Sridhar, Arun R., et al.
Publicado: (2020)

Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2022)

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial
por: Rajasingham, Radha, et al.
Publicado: (2020)

Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin
por: Anupama, B K, et al.
Publicado: (2020)

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
por: Fiolet, Thibault, et al.
Publicado: (2021)

Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure
por: Rakedzon, Stav, et al.
Publicado: (2020)

The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity
por: Tzouvelekis, Argyris, et al.
Publicado: (2020)

Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019
por: Bansal, Pankaj, et al.
Publicado: (2020)

TCT CONNECT-217 Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval
por: Al-Sadawi, Mohammed, et al.
Publicado: (2020)

Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring
por: Ramireddy, Archana, et al.
Publicado: (2020)

Regarding: “Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019”
por: McCullough, Peter A.
Publicado: (2021)

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
por: Tang, Wei, et al.
Publicado: (2020)

Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection
por: Gupta, Salil, et al.
Publicado: (2021)

An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19)
por: Das, Saibal, et al.
Publicado: (2020)

Hydroxychloroquine/immunosuppressants: Nosocomial coronavirus disease 2019 (COVID-19), leucopenia and prolonged persistence of COVID-19 following off-label use: case report
Publicado: (2020)

A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)
por: Chen, Cheng-Pin, et al.
Publicado: (2020)

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
por: Arshad, Samia, et al.
Publicado: (2020)

Deferasirox/hydroxychloroquine: Various toxicities and off-label use in coronavirus disease 2019: case report
Publicado: (2021)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019
por: Egbuna, Chukwuebuka, et al.
Publicado: (2022)

444. Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers in Southeast Michigan
por: Vahia, Amit T, et al.
Publicado: (2020)

Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)—protocol of randomised controlled trial AZIQUINE-ICU
por: Duška, František, et al.
Publicado: (2020)

Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
por: Kim, Ji-Won, et al.
Publicado: (2021)

Interleukin-37 is down-regulated in serum of patients with severe coronavirus disease 2019 (COVID-19)
por: Ahmed, Aeshah A., et al.
Publicado: (2021)

Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae
por: Hamm, Brandon S., et al.
Publicado: (2020)

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial
por: Kamran, Sultan M, et al.
Publicado: (2021)

An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine
por: Mitra, Raman L., et al.
Publicado: (2020)

Coronavirus Disease 2019–COVID-19
por: Dhama, Kuldeep, et al.
Publicado: (2020)

Coronavirus Disease 2019 (COVID-19)
por: Goldust, Mohamad
Publicado: (2022)

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
por: Iwasaka, Sho, et al.
Publicado: (2020)

Screening and Analysis of Serum Protein Biomarkers Infected by Coronavirus Disease 2019 (COVID-19)
por: Feng, Zhaomin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9astedld1helc5kn411o7kbc7l